Apellis Pharmaceuticals Inc (NASDAQ:APLS) currently has a daily average trading volume of 1.65M but it saw 6067558 shares traded in last market. With a market cap of 3.47B USD, the company’s current market price of $28.48 came rising about 2.67 while comparing to the previous closing price of $27.74. In past 52 weeks, the stock remained buoying in the range of price level as high as $73.80 and as low as $26.96. In the recent trading on the day, stock has struck highest price mark of $26.75 while lowest mark touched by it was $28.58.
Taking a look at 20-day trading activity of Apellis Pharmaceuticals Inc (APLS) gives us an average price of $34.37, while its current price level is -61.41% below from 52-week high level whereas it is 5.64% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $36.45 while that of 200 days or SMA-200 reads an average of $48.74. A closer look into the stock’s movement over the week reveals that its volatility is standing at 5.16% during that period while stretching the period over a month that increases to 5.39%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 28.49 which implies that the stock is in oversold territory.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Piper Sandler which initiated the stock as “Neutral” in its note to investors issued on May 31, 2024, recommending a price target of $46 for it. Jefferies upgraded its recommendation for the stock as a “Buy” from “Hold” on February 05, 2024 while assigning a price target range of $68-$80.
Over the week, APLS’s stock price is moving -6.90% down while it is -26.60% when we observe its performance for the past one month. Year-to-date it is -52.42% down and over the past year, the stock is showing a downside performance of -23.32%.
The latest quarterly earnings report issued by the company reported quarterly earnings per share (EPS) of -1.17 beaten by the consensus estimate of -0.85 for the same. The company is expected to be releasing its next quarterly report on 2024-Oct-30, for which analysts forecasted an EPS of -0.29 while estimate for next year EPS is -1.31. In next quarter, company is expected to be making quarterly sales of $214.86M as analysts are expecting the sales for current fiscal year at $787.69M and seeing the company making $1.03B in sales next year. Moreover, analysts are in estimates of $200.84M for current-quarter revenue.
Currently, Apellis Pharmaceuticals Inc’s total number of outstanding shares is 119.56M. Company’s return on investment (ROI) stands at -45.44% and return on equity (ROE) at -109.19%. It has a 149.94 of forward P/E ratio. Stock’s beta reads 0.86. Stock has a price to book (P/B) ratio of 13.11 while price to sale or P/S ratio amounts to 5.52. Its return on asset (ROA) is -36.58% on average.
